Investment Thesis
Sagimet is a development-stage pharmaceutical company with a strong balance sheet ($36.6M cash, zero debt) but severe operating losses (-$10.7M net income on only $2.0M revenue) that are deteriorating year-over-year. The company's negative free cash flow (-$8.6M) and absence of revenue traction indicate an unproven business model with estimated 4+ quarters of cash runway, making this a high-risk investment without demonstrated clinical or commercial validation.
Strengths
- Strong balance sheet with $36.6M cash and minimal liabilities ($7.2M total debt)
- Excellent liquidity position with 20.34x current ratio providing financial flexibility
- Low leverage (0.00x debt-to-equity) enables continued R&D investment without refinancing pressure
Risks
- Massive operating losses (-$11.7M) with only $2.0M revenue demonstrates unproven business model and no clear profitability pathway
- Deteriorating profitability metrics with net income losses worsening 12% YoY and operating margin of -585.6%
- Negative free cash flow (-$8.6M quarterly) indicates elevated burn rate relative to cash reserves with limited runway
Key Metrics to Watch
- Quarterly revenue growth trajectory and pipeline commercialization progress
- Operating cash burn rate relative to cash reserves and estimated runway
- Clinical trial advancement, regulatory approvals, and market adoption of pipeline products
Financial Metrics
Revenue
2.0M
Net Income
-10.7M
EPS (Diluted)
$-0.33
Free Cash Flow
-8.6M
Total Assets
107.8M
Cash
36.6M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-585.7%
Net Margin
-532.5%
ROE
-10.4%
ROA
-9.9%
FCF Margin
-430.6%
Balance Sheet & Liquidity
Current Ratio
20.34x
Quick Ratio
20.34x
Debt/Equity
0.00x
Debt/Assets
6.7%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T10:16:56.182608 |
Data as of: 2026-03-31 |
Powered by Claude AI